United States · Platforms & data · TipRanks

Luye Pharma’s Ruoxinlin Renewed in China’s 2026 Reimbursement Drug List

Published by TipRanks · United States 9 h ago

Detailed summary

Luye Pharma Group ( ($HK:2186) ) has shared an update. Ruoxinlin, approved in China in November 2022 and first included in the reimbursement list in November 2024, ...

Read the full article on TipRanks Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.tipranks.com)

Also worth reading

The Motley Fool

Want to Invest in Top Growth Stocks Like Amazon, Apple, and Microsoft but Avoid Nvidia? Consider This Low-Cost Vanguard ETF That’s Up 24.8% This Year.

Investing.com

ANI Pharmaceuticals president & CEO Lalwani sells $383,400 in shares

Benzinga

Bitcoin Faces Final Capitulation Risk: Could $40,000 Be Next?

Yahoo Finance

He Hears Anthropic CEO Predicts AI Could Cure Cancer and Alzheimer’s Within 10 Years. He’s Skeptical, and Medicare May Cover the Clinical Trial Without Paying for the ...

TheStreet

Nvidia earnings collide with Fed’s biggest AI challenge under Warsh

Stocktwits